Iqvia Holdings Inc.

IQV

US46266C1053

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 10:52:51 2023-12-08 am EST			5-day change	1st Jan Change
215.02 ^USD	+0.01%		-0.80%	+5.02%

Dec. 07	Transcript : IQVIA Holdings Inc. - Special Call	CI
Dec. 05	Iqvia Holdings Insider Sold Shares Worth $2,807,472, According to a Recent SEC Filing	MT

Presenter SpeechTejas Savant (Analysts)All right. Good morning, everyone. My name is Tejas Savant, and I'm the lif...

This article is reserved for subscribers

To unlock the article, SUBSCRIBE!

Already a customer? Log In

Latest news about Iqvia Holdings Inc.

Transcript : IQVIA Holdings Inc. - Special Call	Dec. 07	CI
Iqvia Holdings Insider Sold Shares Worth $2,807,472, According to a Recent SEC Filing	Dec. 05	MT
Let's party like it's 2021	Dec. 04
ANALYST RECOMMENDATIONS : Adobe, Broadcom, Comcast, Fair Isaac, Salesforce...	Dec. 04
Will Powell deliver an early Christmas present?	Dec. 01
ANALYST RECOMMENDATIONS : Abbvie, Boeing, IBM, Lululemon Athletica, Meta Platforms...	Dec. 01
Transcript : IQVIA Holdings Inc. Presents at The 6th Annual Evercore ISI HealthCONx Conference, Nov-29-2023 10:50 AM	Nov. 29	CI
Not good enough!	Nov. 22
ANALYST RECOMMENDATIONS : Best Buy, Glencore, Lowe's, Nvidia, Clorox...	Nov. 22
Palantir Technologies-Led Group Wins Contract to Create Federated Data Platform, NHS England Says	Nov. 21	MT
IQVIA Unit Plans $500 Million Senior Notes Offering	Nov. 14	MT
JPMorgan Cuts Price Target on IQVIA Holdings to $239 From $262, Maintains Overweight Rating	Nov. 13	MT
Transcript : IQVIA Holdings Inc. - Special Call	Nov. 13	CI
Big tech saves the day	Nov. 13
ANALYST RECOMMENDATIONS : Airbnb, Apple, Best Buy, Diageo, Tesla...	Nov. 13
Guggenheim Adjusts Price Target on IQVIA to $220 From $253, Maintains Buy Rating	Nov. 03	MT
North American Morning Briefing : S&P 500 Futures -2-	Nov. 03	DJ
Barclays Adjusts IQVIA Holdings' Price Target to $215 From $245, Keeps Overweight Rating	Nov. 02	MT
UBS Adjusts IQVIA Holdings' Price Target to $240 From $265, Keeps Buy Rating	Nov. 02	MT
Deutsche Bank Adjusts IQVIA Holdings Price Target to $240 From $252, Maintains Buy Rating	Nov. 02	MT
Baird Downgrades IQVIA to Neutral From Outperform, Adjusts Price Target to $202 From $248	Nov. 02	MT
Health Care Up Amid Mixed Earnings -- Health Care Roundup	Nov. 01	DJ
Transcript : IQVIA Holdings Inc., Q3 2023 Earnings Call, Nov 01, 2023	Nov. 01	CI
Sector Update: Health Care	Nov. 01	MT
Sector Update: Health Care Stocks Decline Premarket Wednesday	Nov. 01	MT

Iqvia Holdings Inc. is one of the world's leading companies specializing in information, analytics, research and healthcare services based on technology solutions. Net sales break down by activity as follows: - development of contract research and clinical development solutions and services (54.5%): helping biopharmaceutical companies, medical researchers and healthcare professionals optimize their clinical studies, develop new therapeutic classes, identify treatment needs and assess the efficacy of pharmaceuticals with a view to improving clinical and scientific outcomes; - development of technology and analytics solutions (39.9%): services related to information, analysis, strategic consulting, marketing studies and short-term healthcare-market studies, business processes outsourcing, and management of medical-administrative databases, all aimed at optimizing the performance and commercial strategies of pharmaceutical companies and health workers; - integrated services (5.6%): development and implementation of customized solutions and customer engagement programs, healthcare services, scientific and medical services, etc. Net sales are distributed geographically as follows: Americas (49.4%), Europe and Africa (31.4%) and Asia/Pacific (19.2%).

Sector

Biotechnology & Medical Research

Calendar

2024-02-13 - Q4 2023 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Iqvia Holdings Inc.

Trading Rating :

Investor Rating :

ESG Refinitiv :

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

214.99USD

Average target price

230.52USD

Spread / Average Target

+7.22%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	+5.02%	39 236 M $
SEAGEN INC.	+70.03%	41 191 M $
MODERNA, INC.	-55.04%	30 484 M $
LONZA GROUP AG	-27.37%	27 837 M $
ALNYLAM PHARMACEUTICALS, INC.	-27.28%	22 245 M $
ICON PUBLIC LIMITED COMPANY	+38.48%	22 079 M $
CELLTRION, INC.	+4.49%	16 633 M $
UNITED THERAPEUTICS CORPORATION	-12.97%	11 376 M $
BIO-TECHNE CORPORATION	-16.59%	10 762 M $
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-6.49%	10 401 M $